REGENXBIO slumps after serious side effects mar Duchenne gene therapy results

BioSpace

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.

pharminent May 14, 2026 (Last updated: May 21, 2026)

BioSpace

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday.

Related Stories